ASP II (Ancrod Stroke Program) Study of Acute Viprinex for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute Ischemic Stroke
Phase of Trial: Phase III
Latest Information Update: 02 Jun 2011
At a glance
- Drugs Ancrod (Primary)
- Indications Embolism and thrombosis; Stroke
- Focus Registrational; Therapeutic Use
- Acronyms ASP-II
- 14 Jan 2009 Following a detailed analysis of the recent interim results of this clinical trial, the company has decided not to develop Viprinex further for the treatment of acute ischemic stroke, as reported by Neurobiological Technologies in a media release.
- 17 Dec 2008 Status changed is now discontinued, as reported by clinicaltrials.gov.
- 17 Dec 2008 Status changed from recruiting to suspended. An analysis of trial data is expected in early 2009, results of which will determine whether further development of Ancrod will continue.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History